CORDA Investment Management LLC. Purchases 59,047 Shares of Pfizer Inc. (NYSE:PFE)

CORDA Investment Management LLC. boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 5.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,075,063 shares of the biopharmaceutical company's stock after acquiring an additional 59,047 shares during the period. Pfizer accounts for about 2.2% of CORDA Investment Management LLC.'s holdings, making the stock its 24th biggest position. CORDA Investment Management LLC.'s holdings in Pfizer were worth $27,242,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Clarity Asset Management Inc. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC lifted its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. North Capital Inc. bought a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Bernard Wealth Management Corp. bought a new position in shares of Pfizer in the fourth quarter valued at approximately $30,000. Finally, Curio Wealth LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $32,000. Institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock traded down $0.06 during midday trading on Wednesday, hitting $25.56. 38,339,365 shares of the company's stock were exchanged, compared to its average volume of 41,784,414. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a 50-day moving average price of $23.80 and a two-hundred day moving average price of $24.81. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market cap of $145.32 billion, a P/E ratio of 18.52, a PEG ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the business earned $0.82 earnings per share. The firm's revenue was down 7.8% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.73%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Analyst Ratings Changes

A number of research firms have recently weighed in on PFE. HSBC dropped their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Wolfe Research lifted their price target on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. BMO Capital Markets dropped their price target on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup lifted their price target on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.